This new (and freely available) original research article presents a fast, robust and accurate methodology for correlating compound identity to CYP1A2 potency of inhibitors in metabolic mixtures. The methodology is centered around an at-line nanofractionation platform in which a metabolic mixture is chromatographically separated followed by parallel on-line mass spectrometric (MS) analysis and at-line nanofractionation on high-density microtiter well plates that are then directly exposed to a bioassay.

An original research report by Eun Jeong Cho et al. (University of Texas at Austin) in the January 2018 Issue of SLAS Discovery presents a newly designed biochemical assay that is rapid, sensitive, inexpensive, and high-throughput screening (HTS)-friendly to identify antagonist against aldolase A (ALDOA). 

A new methodology enables the investigation of a large number of structurally conserved enzymes belonging to the Fe(II)/2-oxoglutarate-dependent dioxygenase superfamily.

SLAS Discovery marks the 30^th anniversary of Matrix Assisted Laser Desorption/Ionization Time of Flight (MALDI TOF), the soft ionization technique for analyzing non-volatile biomolecules using mass spectrometry, with a special issue showcasing 10 new research reports.

A review article in the December 2017 issue of SLAS Technology provides important information for life sciences and technology professionals in academia and industry and members of the general public who are interested in antibiotic resistance, general microbial detection principles, in vitro diagnostics, micro- and nanotechnologies, and next generation rapid microbial testing methods.

A new SLAS Technology review article by researchers at the University of Southern California and the University of California, Los Angeles, sheds light on the growing number and more sophisticated designs of theranostic nanoparticles.

SLAS is pleased to announce the addition of Emilio Diez Monedero, Peter Brian Simpson and Severine Tamas-Lhoustau to the Society's Board of Directors. They begin three-year terms in February 2018.

A new SLAS Discovery article available for free ahead-of-print enables researchers to derive more clinically-relevant information from 3D cell culture models.

Discovering new drugs has never been easy and some potential drug targets have historically been viewed as too challenging and thus off limits for prosecution. In a new SLAS Discovery review, authors John S. Lazo et al. of the University of Virginia reflect on the nature of protein tyrosine phosphatases and explores reasons why these enzymes have been eschewed by drug hunters, and how the landscape is beginning to change.

A new report shows how microsystems can be used to understand processes in heart tissue in detail and to test newly developed compounds applied in the treatment of cardiac diseases.

An exploration of the latest understanding of the complex mechanisms behind OA pain offers new possibilities and potential treatment targets for osteoarthritis (OA) pain. New areas of research discussed include the use of combination therapies and the development of biomarkers to target effective pain treatment.

The August 2017 issue of SLAS Technology (formerly the Journal of Laboratory Automation) showcases 10 new reviews and original research reports that illustrate how the progression of research assays from qualitative outputs toward increasingly sensitive quantitative outputs is transforming life sciences and biomedical research and diagnostics by improving the ability of researchers and clinicians to detect and quantify increasingly complex assays.

Information generated by screening tools, readily available therapies and potential pathways to drug development are the cornerstone of informed clinical research and clinical trial design. In a new review in the August 2017 issue of SLAS Discovery (formerly the Journal of Biomolecular Screening), authors Eric Chevet, Ph.D., of Inserm U1242 (Rennes, France) et al. analyze the recent literature and review the impact of unfolded protein response (UPR) in health and disease.